Bosentan Therapy for Pulmonary Arterial Hypertension
New England Journal of MedicinePublished 21 March 2002Open access
Lewis J. Rubin, David B. Badesch, Robyn J. Barst, Nazzareno Galiè, Carol M. Black, Anne Keogh
Citations2,706
SJR quartileQ1
SJR score19.08
SNIP13.47
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
Abstract
The endothelin-receptor antagonist bosentan is beneficial in patients with pulmonary arterial hypertension and is well tolerated at a dose of 125 mg twice daily. Endothelin-receptor antagonism with oral bosentan is an effective approach to therapy for pulmonary arterial hypertension.
Keywords
Medicine
Medicine & Science in Sports & ExercisePsychophysical bases of perceived exertion
16,410 Citations1982Gunnar Borg
A presentation is made of ratio-scaling methods, category methods, especially the Borg Scale for ratings of perceived exertion, and a new method that combines the category method with ratio properties.
New England Journal of MedicineA Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension
2,678 Citations1996Robyn J. Barst, Lewis J. Rubin +18 more
As compared with conventional therapy, the continuous intravenous infusion of epoprostenol produced symptomatic and hemodynamic improvement, as well as improved survival in patients with severe primary pulmonary hypertension.
PubMedThe 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure.
2,085 Citations1985Gordon Guyatt, Michael Sullivan +5 more
It is concluded that the 6-minute walk is a useful measure of functional exercise capacity and a suitable measure of outcome for clinical trials in patients with chronic heart failure.
New England Journal of MedicineExpression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension
1,826 Citations1993Adel Giaid, Masashi Yanagisawa +8 more
Preliminary results suggest that pulmonary hypertension is associated with the increased expression of endothelin-1 in vascular endothelial cells, suggesting that the local production of endethelin- 1 may contribute to the vascular abnormalities associated with this disorder.
New England Journal of MedicinePrimary Pulmonary Hypertension
1,727 Citations1997Lewis J. Rubin
Qualitative histologic examination of lung tissue did not provide a basis for predicting how individual patients would respond to vasodilator agents, but quantitative morphologic analysis of the initial open lung biopsy specimens did prove helpful in predicting acute responsiveness to vasodermal agents and the subsequent clinical course of these patients with unexplained (primary) pulmonary hypertension.
New England Journal of MedicineThe Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension
1,550 Citations1992Stuart Rich, Elizabeth Kaufmann +1 more
This study suggests that high doses of calcium-channel blockers in patients with primary pulmonary hypertension who respond with reductions in pulmonary-artery pressure and pulmonary vascular resistance may improve survival over a five-year period.
The LancetEffects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study
1,518 Citations2001Richard N. Channick, G Simonneau +9 more
Bosentan increases exercise capacity and improves haemodynamics in patients with pulmonary hypertension, suggesting that endothelin has an important role in pulmonary hypertension.
American Journal of Respiratory and Critical Care MedicineClinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary Hypertension: Comparison with Cardiopulmonary Exercise Testing
1,149 Citations2000Shoichi Miyamoto, Noritoshi Nagaya +6 more
It is suggested that the six-minute walk test, a submaximal exercise test, reflects exercise capacity determined by maximal cardiopulmonary exercise testing in patients with PPH, and it is the distance walked in 6 min that has a strong, independent association with mortality.
Annals of Internal MedicineContinuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease
1,072 Citations2000David B. Badesch, Victor F. Tapson +28 more
Continuous epoprostenol therapy improves exercise capacity and cardiopulmonary hemodynamics in patients with pulmonary hypertension due to the scleroderma spectrum of disease.
CirculationPrimary pulmonary hypertension: natural history and the importance of thrombosis.
1,072 Citations1984Valentı́n Fuster, Peter M. Steele +4 more
In more than half the patients undergoing autopsy the major histologic feature was thrombi without any evidence of plexiform lesions, and the two groups were similar with respect to their clinical and hemodynamic features and short survival.
New England Journal of MedicineLong-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue
576 Citations2000Marius M. Hoeper, Michaël Schwarze +6 more
Long-term treatment with aerosolized iloprost is safe and has sustained effects on exercise capacity and pulmonary hemodynamics in patients with primary pulmonary hypertension.
Arthritis & RheumatismPulmonary hypertension in the crest syndrome variant of systemic sclerosis
371 Citations1986Angela M. Stupi, Virginia Steen +4 more
A DLCO less than 45% of predicted in the absence of pulmonary interstitial fibrosis may be an important predictor of the subsequent development of isolated PHT.
Journal of Applied PhysiologyEndothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats
297 Citations1995S. J. Chen, Ya‐Fang Chen +4 more
The hypothesis that endogenous endothelin-1 plays a major role in hypoxic pulmonary vasoconstriction and/or hypertension, right heart hypertrophy, and pulmonary vascular remodeling is supported and it is suggested that endothelins-receptor blockade may be useful in the treatment of hypoxia-induced pulmonary hypertension humans.
The American Journal of MedicinePrevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis
265 Citations1983R. Ungerer, Donald P. Tashkin +7 more
Findings indicate that specific noninvasive studies are helpful in assessing the likelihood of normal or definitely elevated pulmonary artery pressures in patients with progressive systemic sclerosis, but patients with mild pulmonary hypertension are not likely to be identified by these nonin invasive studies.
The LancetOrally active prostacyclin analogue in primary pulmonary hypertension
131 Citations1997Yoshiaki Okano, Takao Yoshioka +3 more
Most patients responded well to long-term beraprost sodium therapy, although there were few acute responses, and all patients had a functional status of III or IV, and ten had a mixed venousoxygen saturation below 63%, which is associated with apoor prognosis.
European Journal of Heart FailureUpdate of REACH-1 and MERIT-HF Clinical Trials in Heart Failure
117 Citations1999Panayiota Mylona, John G.F. Cleland +1 more
The REACH‐1 trial demonstrated that initiation of bosentan therapy is associated with an increased risk of worsening heart failure, however, long‐term therapy with bosenta may have improved symptoms and favourably altered the progression of heart failure.
Pulmonary Pharmacology & TherapeuticsEndothelin-1: a Mediator of Pulmonary Hypertension?
68 Citations1998Margaret R. MacLean
Internal MedicineEndothelin and Collagen Vascular Disease: A Review with Special Reference to Raynaud's Phenomenon and Systemic Sclerosis.
61 Citations1994Kazuhide Yamane
A review of the recent findings of the clinical significance and pathogenetic role of endothelin in collagen vascular diseases, especially in Raynaud's phenomenon and systemic sclerosis finds that a vascular pathogenesis is supported by a variety of clinical and laboratory observations.